Skip to main content

ENGLISH · EVIDENCE OVERVIEW

SR9009
evidence profile

Experimental small molecule / REV-ERB-related research. This is a concise English overview, not a full translation. Read the evidence boundaries and original sources below; the detailed study and risk discussion remains available in Thai.

What do Class, Grade and Risk mean?

SR9009: conceptual scientific illustration for Mitochondrial / Metabolic Research
VISUAL GUIDE · SR9009

Mitochondrial / Metabolic Research

Category-level conceptual illustration, not a map of this molecule's receptor targets. It is not a treatment outcome and does not establish efficacy or safety.

QUICK ANSWER · AEO / GEO

SR9009 is an experimental small molecule, not a SARM or peptide. Genetic studies demonstrate REV-ERB-independent effects, limiting target-specific claims. Cell and mouse results do not establish human fat-loss, endurance or cardiac benefit, and human safety remains unverified.

01

ENTITY FACTS

What should readers identify first?

MOLECULESR9009
PHARMACOLOGYExperimental small molecule / REV-ERB-related research
PRIMECORE CLASSC
EVIDENCE GRADEE
RESEARCH TOPICMitochondrial / Metabolic Research
LAST REVIEWED2026-08-30

What remains unknown?

Insufficient data in the current dataset

What limits these conclusions?

English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty.

Read original excerpts (Thai / mixed language)
  • SR9009 ≠ SARM; mouse metabolism ≠ human exercise benefit; เป้าหมายที่คาดไม่เท่ากับกลไกที่พิสูจน์ครบ

This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.

02

EVIDENCE BOUNDARY

What this overview does not establish

  • An evidence grade does not rank this molecule against another treatment.
  • A molecule name does not establish the identity, purity or regulatory status of a product.
  • Animal, cell or biomarker findings do not automatically establish human clinical benefit.
  • Approval in one country or indication does not transfer globally.

Where can I check the evidence?

Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.

  1. Target-specificity study · PMID 31127047
  2. Cardiac knockout model · PMID 35911512
03

FAQ · ANSWER ENGINE

Frequently asked questions

What is SR9009?

SR9009 is described pharmacologically as Experimental small molecule / REV-ERB-related research. SR9009 is an experimental small molecule, not a SARM or peptide. Genetic studies demonstrate REV-ERB-independent effects, limiting target-specific claims. Cell and mouse results do not establish human fat-loss, endurance or cardiac benefit, and human safety remains unverified.

Does SR9009 have strong evidence?

PrimeCoreBio records Evidence Grade E. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.

Is SR9009 approved everywhere?

No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.

Medical Disclaimer

Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.

Contact PrimeCoreBio

Choose a contact channel

General information only · No sales or medical advice